News | November 16, 2024
Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Growth markets revenue increased by 44 YoY to Rs. 812 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Subscribe To Our Newsletter & Stay Updated
